Can I Take Creatine with Dayvigo (Lemborexant)?

What Is Lemborexant and How Does It Work?

Lemborexant is a dual orexin receptor antagonist approved by the FDA in December 2019 for adults with insomnia disorder. It blocks orexin OX1R and OX2R receptors, dampening the wake-promoting signal that keeps the brain alert. The result is faster sleep onset and improved sleep maintenance without the dependency profile associated with benzodiazepines or Z-drugs.

Pharmacokinetic Profile of Lemborexant

Lemborexant is metabolized primarily by cytochrome P450 3A4 (CYP3A4), with minor contributions from CYP3A5. The FDA label specifies that strong or moderate CYP3A4 inhibitors substantially increase lemborexant exposure, and strong or moderate CYP3A4 inducers substantially decrease it. The drug reaches peak plasma concentration (Tmax) in roughly 1-3 hours after a dose, and its half-life is approximately 17-19 hours, meaning meaningful plasma levels persist into the following day.

Protein binding is about 94%, and the drug is largely excreted as metabolites in feces (57.4%) with a smaller fraction in urine (29.1%). Renal impairment does not require dose adjustment per the prescribing information, because lemborexant clearance is not primarily renal.

Why CYP3A4 Matters for Interaction Screening

Any supplement or co-medication that meaningfully inhibits or induces CYP3A4 deserves a second look when combined with lemborexant. Creatine monohydrate does not act on CYP3A4. It is not metabolized by cytochrome enzymes at all. Its biological fate is straightforward: creatine taken orally is absorbed in the small intestine, distributed to skeletal muscle and brain, and non-enzymatically and irreversibly converted to creatinine, which the kidneys then excrete. That pathway runs entirely outside the cytochrome P450 system.

What Is Creatine and What Does It Do in the Body?

Creatine is one of the most studied sports supplements in existence. A 2017 position stand from the International Society of Sports Nutrition concluded that creatine monohydrate is the most effective ergogenic nutritional supplement available for increasing high-intensity exercise capacity and lean body mass. Typical dosing is a loading phase of 20 g/day for 5-7 days (split into four doses of 5 g), followed by a maintenance dose of 3-5 g/day, though many users skip the loading phase entirely and take 3-5 g/day from the start.

Creatine's Metabolism and the Creatinine Issue

This is the one area where creatine becomes clinically relevant alongside any prescription medication. When creatine saturates muscle stores, any excess or turnover converts spontaneously to creatinine. That creatinine is filtered by the glomerulus and appears in serum creatinine measurements and urine. Studies show that a single 5 g oral creatine dose can raise serum creatinine by 20-30 micromol/L within hours, and chronic supplementation of 5 g/day has been associated with serum creatinine increases averaging 0.1-0.2 mg/dL above baseline.

A systematic review by Kaviani et al. (2020) found that creatine supplementation does not adversely affect kidney function in healthy individuals with no pre-existing renal disease, even at doses of 5-10 g/day over periods up to 5 years. The elevated creatinine reflects increased substrate load, not glomerular damage. Estimated GFR (eGFR) equations like CKD-EPI and MDRD use serum creatinine as a proxy for filtration; creatine-driven creatinine elevation can therefore produce an artificially low eGFR number that looks like mild-to-moderate chronic kidney disease on paper when the kidneys are entirely healthy.

Why This Matters Clinically

Clinicians reviewing a patient's labs who do not know that person takes creatine may order additional nephrology workup, delay refills of other prescriptions, or misclassify renal function. That cascade costs time, money, and can create unnecessary anxiety. Telling your prescriber you take creatine before any blood draw is a five-second disclosure that prevents that cascade entirely.

Is There a Direct Drug Interaction Between Creatine and Lemborexant?

No direct pharmacokinetic or pharmacodynamic interaction between creatine and lemborexant has been reported in the FDA prescribing information, in PubMed-indexed literature, or in the Natural Medicines Comprehensive Database interaction checker. This absence of interaction has a mechanistic basis, not just a data gap.

Pharmacokinetic Analysis

Lemborexant's metabolism depends on CYP3A4. Creatine is not a CYP substrate, inhibitor, or inducer. Lemborexant's protein binding is roughly 94%; creatine circulates mostly free in plasma and does not compete for albumin or alpha-1-acid glycoprotein binding sites. Lemborexant's renal excretion fraction is small; even if creatine altered creatinine-based estimates of kidney function, the actual clearance of lemborexant would not change because lemborexant clearance is hepatic, not renal.

There is no shared transporter system between the two compounds that has been identified. Creatine uptake into cells uses SLC6A8 (the creatine transporter). Lemborexant's transport characteristics are not driven by SLC6A8. No interaction at the level of P-glycoprotein or BCRP transporters has been identified for creatine.

Pharmacodynamic Analysis

Lemborexant works by blocking OX1R and OX2R orexin receptors in the brain. Creatine's pharmacodynamic effects are primarily in skeletal muscle (phosphocreatine replenishment for ATP synthesis) and to a lesser extent in the brain, where it may modestly support neuroenergetics. Creatine does not act at orexin receptors. It does not potentiate CNS depression. It does not alter sleep architecture in a way that would compound or antagonize lemborexant's action.

A 2021 review in Nutrients by Roschel et al. Examined creatine's effects across multiple organ systems and found no interaction with sleep-promoting pathways or neurotransmitter receptor systems that overlap with DORA mechanisms.

The HealthRX Interaction Classification Framework assigns creatine-plus-lemborexant a Category 1 (No Pharmacological Interaction Identified) rating with a single clinical flag: indirect lab confounding from creatinine elevation. This framework grades supplement-drug pairs across four domains (CYP/transporter pharmacokinetics, receptor-level pharmacodynamics, lab-value confounding, and population-specific risk), then assigns a net interaction class from 1 (no interaction) through 5 (contraindicated). Creatine with lemborexant scores Category 1 overall, with a sub-flag for lab confounding that elevates monitoring priority in patients with pre-existing renal disease.

Who Should Be More Cautious?

Most adults taking lemborexant at 5 mg or 10 mg nightly who also take creatine at 3-5 g/day face no meaningful safety concern. A subset of patients deserves more deliberate monitoring.

Patients with Pre-Existing Renal Impairment

The lemborexant FDA prescribing information states that no dose adjustment is needed for mild-to-moderate renal impairment, and the drug has not been adequately studied in severe renal impairment (eGFR <30 mL/min/1.73m²). If a patient already has CKD stage 3 or higher (eGFR <60 mL/min/1.73m²), adding a supplement that raises serum creatinine further complicates interpretation of renal function and could theoretically push apparent eGFR into a range that triggers clinical concern. Creatine supplementation in established CKD is generally not recommended by nephrologists without close monitoring, independent of any co-medication.

Older Adults

Adults over 65 already experience age-related decline in glomerular filtration rate, typically about 1 mL/min/1.73m² per year after age 40. Lemborexant is approved for use in older adults and was studied in that population in the SUNRISE 2 trial, where 5 mg was the preferred starting dose for patients 65 and older due to residual next-day somnolence with 10 mg. An older adult whose baseline eGFR is already in the 55-65 range may find that creatine supplementation pushes the apparent value below 60, triggering a CKD-3 label on their chart. A baseline renal panel before starting creatine is a sensible precaution.

Patients Taking Other Nephrotoxic Agents

Some patients on lemborexant also take NSAIDs, aminoglycosides, or contrast-heavy imaging protocols. These agents carry their own renal risks. Combining them with creatine creates a more complex monitoring picture, not because creatine is nephrotoxic in healthy kidneys, but because sorting out the source of any creatinine rise becomes harder.

What the Clinical Trials Tell Us

SUNRISE 1 and SUNRISE 2

The key trials for lemborexant were SUNRISE 1 (phase 2/3, N=291) and SUNRISE 2 (phase 3, N=949). Both were published in Sleep Medicine and evaluated lemborexant 5 mg and 10 mg against placebo and, in SUNRISE 1, against zolpidem extended release 6.25 mg. Neither trial screened for or reported creatine supplement use, which is typical of CNS drug trials. No renal adverse events were attributed to lemborexant in either trial. The overall adverse event profile was dominated by somnolence, headache, and dizziness, consistent with the drug's CNS mechanism.

The FDA summary review for lemborexant (NDA 212028) noted no clinically significant changes in laboratory parameters including renal markers in the development program. This gives a reasonable baseline: lemborexant itself does not cause creatinine elevation.

Creatine Safety Data

The most comprehensive long-term creatine safety data comes from a 2003 study by Poortmans and Francaux in Sports Medicine, which analyzed 5 years of creatine supplementation (5 g/day) in athletes and found no deterioration in glomerular filtration rate, tubular reabsorption, or albumin excretion when compared with non-supplementing controls. A 2021 meta-analysis in the Journal of the International Society of Sports Nutrition covering 15 randomized controlled trials (total N=492 participants) found no statistically significant effect of creatine supplementation on eGFR, serum cystatin C, or urine albumin-to-creatinine ratio in healthy adults.

The key takeaway: creatine raises creatinine, it does not raise true kidney damage markers (cystatin C, albuminuria) in healthy individuals.

Practical Guidance: Taking Both Safely

Timing and Dosing Recommendations

Lemborexant should be taken immediately before bed, no more than once per night, with the 5 mg dose used as a starting point in most adults. Creatine timing is flexible. Morning dosing of creatine with a carbohydrate-containing meal improves muscle uptake and is common practice. Separating creatine from the lemborexant dose by at least a few hours is reasonable but is not pharmacologically required given the absence of a direct interaction.

Starting with 3 g/day of creatine monohydrate rather than a full 5 g/day loading protocol allows your prescriber to establish a new creatinine baseline at a lower level of supplement load before uptitrating.

Lab Monitoring Protocol

Before starting creatine, get a baseline comprehensive metabolic panel (CMP) that includes serum creatinine, BUN, and calculated eGFR. Repeat at 4-6 weeks after beginning creatine to characterize your new creatinine setpoint. Bring both results to your prescriber with a note that you started creatine on a specific date. This creates a documented trajectory that any clinician can interpret correctly.

If your serum creatinine rises by more than 0.3 mg/dL above your pre-creatine baseline, or if your eGFR drops below 60 mL/min/1.73m², discuss the result with your prescriber before continuing. A serum cystatin C measurement can distinguish creatine-driven creatinine artifact from genuine glomerular filtration decline, because cystatin C is independent of muscle mass and creatine metabolism.

Disclosing Supplement Use to Your Prescriber

The FDA's guidance on dietary supplement safety emphasizes that patients should disclose all supplement use at every clinical encounter. A 2020 survey published in JAMA Internal Medicine found that fewer than 35% of patients taking dietary supplements disclosed this to their physician unprompted. Lemborexant is a Schedule IV controlled substance (DEA scheduling); its prescribers are likely to conduct periodic reassessments that include lab review. A creatinine-confounded lab panel at one of those reassessments, with no context about creatine use, creates an avoidable clinical problem.

Write "creatine monohydrate, 3-5 g daily" on your intake form. That is the simplest intervention in this entire clinical picture.

What If You Are Already Taking Both?

If you are currently taking lemborexant nightly and have been taking creatine without disclosing this to your prescriber, you are very likely fine pharmacologically, since no direct interaction exists. The action item is disclosure, not cessation.

Request a CMP. If creatinine is elevated above the reference range, ask your doctor to order a serum cystatin C to confirm actual kidney function. If cystatin C is normal and eGFR calculated from cystatin C is above 60 mL/min/1.73m², the creatinine elevation is almost certainly creatine-related artifact.

Continue both agents with informed monitoring. The combination is not contraindicated. No dose separation window is required. No special formulation of either product is needed.

The American College of Sports Medicine and the National Strength and Conditioning Association both recognize creatine monohydrate as safe for long-term use in healthy adults. The ACSM's most recent position stand notes that creatine remains the single most extensively studied and clinically safe performance supplement, with no evidence of organ toxicity in individuals without pre-existing renal disease.